Shares of Stemline Therapeutics, Inc. (NASDAQ:STML) have been given an average rating of “Buy” by the nine brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $32.60.

A number of brokerages recently issued reports on STML. ValuEngine downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. HC Wainwright set a $34.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, June 14th. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th.

Shares of Stemline Therapeutics (NASDAQ STML) opened at 12.20 on Thursday. The company’s 50 day moving average price is $10.31 and its 200 day moving average price is $9.02. The company’s market cap is $286.15 million. Stemline Therapeutics has a 12 month low of $5.50 and a 12 month high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.18). Stemline Therapeutics had a negative net margin of 4,176.84% and a negative return on equity of 67.35%. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, equities analysts expect that Stemline Therapeutics will post ($2.56) EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of STML. FMR LLC grew its holdings in shares of Stemline Therapeutics by 72.1% during the 1st quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock worth $21,708,000 after acquiring an additional 1,063,457 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Stemline Therapeutics by 27.6% during the 1st quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock worth $9,289,000 after acquiring an additional 235,000 shares during the period. Vanguard Group Inc. grew its holdings in shares of Stemline Therapeutics by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after acquiring an additional 204,228 shares during the period. AXA grew its holdings in shares of Stemline Therapeutics by 44.9% during the 2nd quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after acquiring an additional 195,022 shares during the period. Finally, Artal Group S.A. grew its holdings in shares of Stemline Therapeutics by 150.0% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,300,000 after acquiring an additional 150,000 shares during the period. Hedge funds and other institutional investors own 48.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/12/stemline-therapeutics-inc-stml-given-average-recommendation-of-buy-by-brokerages.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.